• RNA Clean and Concentrator Kit: Enabling Precision RNA Purif

  2026-05-07

  Discover how the RNA Clean and Concentrator Kit empowers precise RNA purification from enzymatic reactions, with advanced analysis linking RNA cleanup to robust functional genomics and disease modeling. Explore unique insights and protocol parameters for rigorous, reproducible workflows.

• Poly(I:C) as a Translational Immune Modulator: Mechanisms an

  2026-05-06

  This thought-leadership article explores the dual mechanistic and strategic role of Poly(I:C), a synthetic double-stranded RNA analog and TLR3 agonist, in driving next-generation translational research. By bridging evidence from plant and mammalian immunity, we illuminate how Poly(I:C) enables robust modeling of innate immune activation, dendritic cell maturation, and stem cell-derived cardiomyocyte advancement. We contextualize APExBIO's Poly(I:C) (SKU B5551) within the competitive reagent landscape, offering actionable protocol guidance, evidence-based insights, and a forward-looking vision for leveraging dsRNA analogs in immunology and regenerative medicine.

• Lopinavir (ABT-378): Precision Tool for HIV and Emerging Vir

  2026-05-06

  Discover how Lopinavir (ABT-378) enables advanced HIV protease inhibition and cross-pathogen antiviral research. This article uniquely explores serum-interference resilience, resistance mutation profiling, and new assay design insights, grounded in recent virology breakthroughs.

• Aβ42 Peptide Fibrils Stimulate Microglial Phagocytosis in AD

  2026-05-05

  Kopec and Carroll's seminal study demonstrated that fibrillar Amyloid β-Peptide (1-42) (Aβ42) robustly induces a phagocytic response in murine microglia, acting as an immune signal central to Alzheimer's disease pathology. Their findings clarify the functional interaction between amyloid aggregates and microglial activation, with implications for understanding plaque progression and immune modulation.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-05-05

  This study uncovers a novel dual-action mechanism by which specific p38α MAPK inhibitors not only block kinase activity but also promote dephosphorylation via conformational modulation. The findings suggest new strategies for designing more potent and selective kinase inhibitors in inflammation and cytokine signaling research.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Canc

  2026-05-04

  This study presents the preclinical pharmacological characterization of anlotinib hydrochloride, a highly selective multi-target tyrosine kinase inhibitor with potent activity against VEGFR2. The results demonstrate anlotinib’s superior anti-angiogenic efficacy and selectivity, offering valuable insights for researchers developing next-generation anti-angiogenic strategies in cancer research.

• Applied Workflows Using Bromodomain Inhibitor, (+)-JQ1

  2026-05-04

  Bromodomain Inhibitor, (+)-JQ1 (SKU A1910) stands out in translational research for its precise targeting of BET bromodomains and unique versatility—from apoptosis assays in cancer biology to non-hormonal male contraception models. This guide delivers actionable experimental workflows, troubleshooting strategies, and comparative insights to maximize the reliability and impact of your (+)-JQ1 studies.

• Vincristine Sulfate: Precision Microtubule Disruption in Can

  2026-05-03

  Vincristine sulfate empowers cancer research workflows with high-specificity inhibition of microtubule dynamics, enabling robust in vitro and in vivo antitumor assays. This guide delivers advanced protocols, troubleshooting strategies, and cross-domain translational insights for achieving reproducible results with APExBIO’s rigorously validated compound.

• Quizartinib (AC220): Precision FLT3 Inhibition in AML Resear

  2026-05-02

  Quizartinib (AC220) sets a new standard for selective inhibition of FLT3 in acute myeloid leukemia (AML) research, enabling robust assay reproducibility and actionable insights into resistance mechanisms. This article delivers practical, evidence-backed workflows and advanced troubleshooting to empower bench scientists tackling FLT3-driven malignancies.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-05-01

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase and MAPK pathways to enhance antitumor immune responses and modulate the tumor microenvironment in liver cancer. The findings underscore the therapeutic potential of dual-pathway inhibition for overcoming immunosuppression, offering mechanistic insights relevant to researchers developing mitochondrial and apoptosis assays.

• Patient-Derived Gastric Cancer Assembloids: Tumor–Stroma Mod

  2026-05-01

  This study introduces a robust method to create gastric cancer assembloids by integrating patient-matched tumor organoids and stromal cell subpopulations. The approach more faithfully recapitulates tumor heterogeneity and microenvironmental influences, enabling deeper investigation into drug responses, resistance mechanisms, and personalized therapy optimization.

• Foretinib (GSK1363089): Reliable Multikinase Inhibition in C

  2026-04-30

  This article guides biomedical researchers through real-world challenges in cell viability and cytotoxicity assays, illustrating how Foretinib (GSK1363089), SKU A2974, delivers reproducible multikinase inhibition for tumor cell growth and metastasis models. Practical Q&A scenarios and protocol recommendations help optimize experimental workflows using validated, quantitative data.

• Neutrophil Extracellular Traps in CML: TKI-Specific Modulati

  2026-04-30

  This study demonstrates that neutrophil extracellular trap (NET) formation is significantly elevated in chronic myeloid leukemia (CML) and that different tyrosine kinase inhibitors (TKIs) variably modulate this process. The findings provide mechanistic insight into the intersection of TKI therapy, NET biology, and vascular risk, guiding future research and therapeutic strategies.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im

  2026-04-29

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, closely recapitulating tumor heterogeneity and microenvironment. The model enables detailed study of drug resistance mechanisms and personalized therapeutic responses, advancing translational cancer research.

• BMN 673 (Talazoparib): Transforming DNA Repair Deficiency Re

  2026-04-29

  BMN 673 (Talazoparib) empowers cancer researchers with industry-leading PARP1/2 inhibition and robust PARP-DNA complex trapping, elevating both mechanistic and translational workflows. Its exceptional selectivity and potency enable precise interrogation of homologous recombination deficient tumors and complex DNA repair landscapes.

14511 records 1/968 page Next 12345 下5页 Last page